Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.
[hodgkin lymphoma, classical]
Despite
the
relative
success
of
chemotherapy
for
Hodgkin
lymphoma
(
HL
)
and
systemic
anaplastic
large
cell
lymphoma
(
ALCL
)
,
novel
therapeutic
agents
are
needed
for
refractory
or
relapsed
patients
.
Targeted
immunotherapy
has
emerged
as
a
novel
treatment
option
for
these
patients
.
Although
unconjugated
anti-cluster
of
differentiation
(
CD
)
30
antibodies
showed
minimal
antitumor
activity
in
early
clinical
trials
,
development
of
antibody-drug
conjugates
(
ADCs
)
appears
promising
.
Brentuximab
vedotin
is
an
ADC
composed
of
an
anti-
CD
30
antibody
linked
to
a
potent
microtubule-disrupting
agent
monomethyl
auristatin
E
(
MMAE
)
.
It
has
the
ability
to
target
CD
30
-
positive
tumor
cells
and
,
once
bound
to
CD
30
,
brentuximab
vedotin
is
internalized
and
MMAE
is
released
to
induce
cell
cycle
arrest
and
apoptosis
.
In
two
Phase
II
trials
,
objective
response
was
reported
in
75
%
and
86
%
of
patients
with
refractory
or
relapsed
HL
and
systemic
ALCL
,
respectively
,
with
an
acceptable
toxicity
profile
.
Based
on
these
studies
,
the
US
Food
and
Drug
Administration
(
FDA
)
granted
accelerated
approval
of
brentuximab
vedotin
in
August
2011
for
the
treatment
of
refractory
and
relapsed
HL
and
ALCL
.
We
review
the
key
characteristics
of
brentuximab
vedotin
,
clinical
data
supporting
its
therapeutic
efficacy
,
and
current
ongoing
trials
to
explore
its
utility
in
other
CD
30
-
positive
malignancies
.
Diseases
Validation
Diseases presenting
"hodgkin lymphoma"
symptom
esophageal adenocarcinoma
hodgkin lymphoma, classical
monosomy 21
primary effusion lymphoma
severe combined immunodeficiency
systemic capillary leak syndrome
waldenström macroglobulinemia
This symptom has already been validated
